Sublingual Buprenorphine Through Telemedicine vs In-Person Care as Usual

Meeting DSM-5 criteria for substance use disorder other than opioid as the primary diagnosis that would compromise safety of participation in the trial as determined by the study physician, such as an alcohol or sedative hypnotic use disorder that requires detoxification

Having a comorbid psychiatric diagnosis that might interfere with participation or make participation hazardous, such as a psychotic disorder including schizophrenia or schizoaffective disorder

Concurrent methadone, buprenorphine, or vivitrol maintenance treatment

Known history of allergy, intolerance, or hypersensitivity to candidate medication (buprenorphine)